Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

Cost: Free

View Offer chevron_right

Details

Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

  • Describe the gene therapy and its anticipated impact on hemophilia B therapy
  • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
  • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
  • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.